Revenue via LymPro will start to roll in during th
Post# of 30013
Plenty of cash to keep the company going, no doubt about that. But at the expense of shareholders, most likely yes (at least for a little while longer..). But that's the price you pay for being invested in a pre revenue start up biotech.
I'm okay with it, due the potential, that's why I'm still here..
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)